Edition:
United States

XOMA Corp (XOMA.OQ)

XOMA.OQ on NASDAQ Stock Exchange Global Market

20.66USD
22 Jun 2018
Change (% chg)

$0.08 (+0.39%)
Prev Close
$20.58
Open
$20.69
Day's High
$21.05
Day's Low
$19.58
Volume
577,645
Avg. Vol
54,830
52-wk High
$37.25
52-wk Low
$6.40

Latest Key Developments (Source: Significant Developments)

Xoma Corp - Entered Loan And Security Agreement Of Up To $20.0 Million
Tuesday, 8 May 2018 07:27am EDT 

May 8 (Reuters) - XOMA Corp ::XOMA CORP - CO, UNITS ENTERED LOAN AND SECURITY AGREEMENT UNDER WHICH LENDER AGREED TO LEND UP TO $20.0 MILLION IN A SERIES OF TERM LOANS - SEC FILING.XOMA CORP - CO MAY BORROW ADDITIONAL $20.0 MILLION FROM LENDER SUBJECT TO CERTAIN CONDITIONS.  Full Article

Xoma Corp Files For Mixed Shelf Of Up To $300 Million
Wednesday, 7 Mar 2018 05:15pm EST 

March 7 (Reuters) - Xoma Corp ::XOMA CORP FILES FOR MIXED SHELF OF UP TO $300 MILLION – SEC FILING‍​.  Full Article

Xoma Reports Q4 Loss Per Share $0.16
Wednesday, 7 Mar 2018 04:05pm EST 

March 7 (Reuters) - Xoma Corp ::XOMA REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q4 REVENUE $5.4 MILLION VERSUS $500,000.QTRLY LOSS PER SHARE $0.16.  Full Article

XOMA Announces Exclusive License Agreement For XOMA 358 With Rezolute Inc.
Thursday, 7 Dec 2017 08:35am EST 

Dec 7 (Reuters) - XOMA Corp ::XOMA ANNOUNCES EXCLUSIVE LICENSE AGREEMENT FOR XOMA 358 WITH REZOLUTE, INC..XOMA CORP - UNDER LICENSE AGREEMENT, CO IS ENTITLED TO RECEIVE UP TO APPROXIMATELY $240 MILLION IN EXCHANGE FOR GLOBAL XOMA 358 RIGHTS.XOMA CORP - TO RECEIVE PAYMENTS AS REZOLUTE ACHIEVES SPECIFIC MILESTONES ASSOCIATED WITH FINANCING ACTIVITIES, CLINICAL DEVELOPMENT SUCCESS​, OTHERS.XOMA-‍TERMS OF AGREEMENT INCLUDE ALLOCATION OF $5 MILLION IN SHARES OF REZOLUTE TO CO,$13 MILLION IN CASH,STOCK TO BE PAID AS REZOLUTE COMPLETES SOME MILESTONES​.XOMA SAYS IS ALSO ENTITLED TO RECEIVE LOW SINGLE-DIGIT ROYALTIES ON NET SALES OF AB101, OTHER PRODUCTS DEVELOPED FROM CERTAIN OF REZOLUTE PLATFORMS.XOMA CORP - REZOLUTE IS RESPONSIBLE FOR ALL DEVELOPMENT, REGULATORY, MANUFACTURING AND COMMERCIALIZATION ACTIVITIES UNDER LICENSE.XOMA SAYS REZOLUTE PLANS TO ADVANCE XOMA 358'S CLINICAL DEVELOPMENT IN 2018.XOMA CORP - ELIGIBLE TO RECEIVE ROYALTIES RANGING FROM HIGH SINGLE-DIGITS TO MID-TEENS ON NET SALES OF XOMA 358.  Full Article

Xoma posts Q3 revenue of $36.2 million
Monday, 6 Nov 2017 04:05pm EST 

Nov 6 (Reuters) - Xoma Corp :Xoma reports third quarter 2017 financial results.Q3 revenue $36.2 million versus $600,000.Q3 revenue view $690,000 -- Thomson Reuters I/B/E/S.Qtrly diluted net income per share available to common stockholders $1.98.  Full Article

XOMA Earns $3 million milestone payment from its license agreement with Nanotherapeutics
Monday, 11 Sep 2017 07:00am EDT 

Sept 11 (Reuters) - XOMA Corp :XOMA earns $3 million milestone payment from its license agreement with nanotherapeutics.  Full Article

Novartis Pharma reports a 6.6 percent passive stake in Xoma Corp as of August 24, 2017
Tuesday, 5 Sep 2017 05:31pm EDT 

Sept 5 (Reuters) - Novartis AG :Novartis Pharma AG reports a 6.6 percent passive stake in Xoma Corp as of august 24, 2017 - SEC filing‍​.  Full Article

XOMA Q2 revenue $10.9 million
Tuesday, 8 Aug 2017 04:30pm EDT 

Aug 8 (Reuters) - XOMA Corp ::XOMA reports second quarter 2017 financial results.Q2 revenue $10.9 million versus I/B/E/S view $10.4 million.XOMA Corp says current cash balance sufficient to fund operations through August 2018.Qtrly net income per share available to common stockholders $0.02.  Full Article

Xoma Q1 loss per share $2.37
Tuesday, 9 May 2017 04:05pm EDT 

May 9 (Reuters) - Xoma Corp :Xoma reports first quarter 2017 financial results.Q1 revenue $300,000 versus $4.0 million.Q1 basic and diluted net loss per share available to common shareholders of $2.37.Qtrly loss per share $2.37.  Full Article

Xoma announces positive results from its phase 2 study of prolactin inhibition
Monday, 24 Apr 2017 07:00am EDT 

April 24 (Reuters) - Xoma Corp :Xoma announces positive results from its phase 2 proof-of-concept study of prolactin inhibition.Xoma Corp says has achieved positive phase 2 proof-of-concept results for x213 in physiological hyperprolactinemia.Xoma Corp - while study was not intended, or powered to show statistical significance, it demonstrated that X213 was safe and well tolerated.  Full Article

BRIEF-XOMA Reports Qtrly Loss Per Share $0.46

* QTRLY LOSS PER SHARE $0.46 Source text for Eikon: Further company coverage: